References
- Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83–90
- Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990;75:18S–25S; discussion 31S–35S
- Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnance progestin (trimeges-tone). Gynecol Endocrinol 1999;13:316–26
- Stevenson JC Cardiovascular effects of oestro-gens. J Steroid Biochem Mol Biol 2000;74:387–93
- Jacobs DRJ, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131 :32–47
- Taitel HF, Kafrissen ME. Norethindrone — a review of therapeutic applications. Int J Fertil Menopausal Stud 1995;40:207–23
- Garfagnini A, Devoto G, Rosselli P, Boggiano P, Venturini M. Relationship between HDL-cho-lesterol and apolipoprotein Al and the severity of coronary artery disease. Eur Heart J 1995;16:465–70
- Farish E, Fletcher CD, Hart DM, Dagen MM, Parkin DE. Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta 1986;159:147–51
- Spencer C, Crook D, Ross D, Cooper A, White-head M, Stevenson J. A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. Br J Obstet Gynaecol 1999;106: 948–53
- Tikkanen MJ. Estrogens, progestins and lipid metabolism. Maturitas 1996;23 ( Suppl ) : S51–5
- Meuwissen JH, Beijers-De Bie L, Vihtamaki T, et al. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel ortrimegestone.Gyne colEndo crinol2002;16:155–62
- Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
- Walldius G, Jungner I, Kolar W, Holme I, Steiner E. High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction. First report from the AMORIS (Apolipoprotein related MOrtality RISk) study. Blood Press Suppl 1992;4:35–42
- Wood D, De Backer G, Faergeman 0, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommenda-tions of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434–503
- Muesing RA, Forman MR, Graubard BI, et al. Cyclic changes in lipoprotein and apolipoprotein levels during the menstrual cycle in healthy premenopausal women on a controlled diet. J Clin Endocrinol Metab 1996;81:3599–603
- van Lennep JE, Westerveld HT, van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. A rterioscler Thromb Vas c Biol 2000;20:2408–13
- Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 1991;266:3080–6
- Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999;354:1341–6
- Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999;22:352–5
- Fielding CJ, Bist A, Fielding PE. Caveolin mRNA levels are up-regulated by free cholester-ol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci USA 1997;94:3753–8
- Arakawa R, Abe-Dohmae S, Asai M, Ito JI, Yokoyama S. Involvement of caveolin-1 in cholesterol enrichment of high density lipopro-tein during its assembly by apolipoprotein and THP-1 cells. J Lipid Res 2000;41:1952–62
- Kojima K, Abe-Dohmae S, Arakawa R, Mur-akami I, Suzumori K, Yokoyama S. Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 2001;1532:173–84